跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
COMIRNATY ORIGINAL & OMICRON BA.4/BA.5
Authorized
STANDARD
COMIRNATY ORIGINAL & OMICRON BA.4/BA.5
BioNTech Manufacturing GmbH
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
19f12d4b2aa07b01
Company
BioNTech Manufacturing GmbH
Type
Standard
Approval Details
Approval Id
19f12d4b2aa07b01
Drug Approval Canada Name
COMIRNATY ORIGINAL & OMICRON BA.4/BA.5
Product Name
COMIRNATY ORIGINAL & OMICRON BA.4/BA.5
Status
Cancelled Post Market
Status Date
2024-05-03
Original Market Date
2022-12-19
Din
02533197
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BN01 COVID-19, RNA-BASED VACCINE
Atc Name
j 07 bn 01
Aig Number
0264101002
Company Name
BioNTech Manufacturing GmbH
Company Address
An Der Goldgrube 12, Mainz, Rheinland-Pfalz, Germany, 55131
Company Detail Path
/organization/biontech-manufacturing-gmbh
Company Information
Pharmaceutical Company Name
BioNTech Manufacturing GmbH
Country Name
Germany
Province Name
rheinland-pfalz
Active Ingredients
FAMTOZINAMERAN
5 MCG / 0.2 ML
TOZINAMERAN
5 MCG / 0.2 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
19f12d4b2aa07b01
Type
Standard
Back to Health Canada Approvals
COMIRNATY ORIGINAL & OMICRON BA.4/BA.5 - Health Canada Drug Approval Details